Novel, potent and selective inhibitor of the leucine-rich repeat kinase-2 (LRRK2), IC50 = 1.28 nM. Also inhibits G2019S mutant LRRK2, IC50 = 1.85 nM1. Attenuates the neuronal damage elicited by the action of LRRK2 G2019S mutant in primary human neurons (
* VAT and and shipping costs not included. Errors and price changes excepted